BURST CME™ Activity 3: Exploring Combination Strategies in HR+/HER2– MBC: Where Do Oral SERDs Fit In?

Activity Overview

As the oral selective estrogen receptor degrader (SERD) class matures, attention is shifting from monotherapy to rational combination strategies intended to deepen and prolong disease control in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC). Combining oral SERDs with CDK4/6 inhibitors or agents targeting the PI3K/AKT/mTOR (PAM) pathway provides a mechanistically grounded approach to overcoming endocrine resistance. However, these regimens also raise practical questions regarding patient selection, treatment sequencing, and additive toxicities.

In this activity, 2 experts examine the emerging evidence for oral SERD–based combinations. They review data about SERD–CDK4/6 inhibitor combinations, including evolving first-line paradigms and later-line umbrella trial results from EMBER-3 and ELEVATE. They also discuss SERD–PAM pathway strategies, including giredestrant plus everolimus (evERA) and capivasertib- and gedatolisib-based combinations. Finally, the faculty explore how to incorporate these data into individualized treatment decisions and outline evidence-based approaches to anticipating, monitoring, and managing adverse events associated with targeted combination regimens.

Target Audience

This educational program is primarily directed toward a global audience of medical oncologists, advanced practice providers, nurses, and other health care professionals who are involved in the management of patients with advanced breast cancer or MBC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based strategies for patients with HR+/HER2– MBC
• Apply evidence-based approaches to anticipate, monitor, and manage adverse effects associated with targeted therapies for patients with HR+/HER2– MBC

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.